Difference between revisions of "Immune Tolerance"
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | = | + | {{review}} |
+ | |||
+ | =Immune Tolerance= | ||
Immunological tolerance occurs when there is unresponsiveness towards particular antigens, so any further immune responses are prevented or suppressed. Tolerance is required to prevent: | Immunological tolerance occurs when there is unresponsiveness towards particular antigens, so any further immune responses are prevented or suppressed. Tolerance is required to prevent: | ||
* Potentially harmful inflammatory responses towards innocuous substances, such as air-borne or food molecules | * Potentially harmful inflammatory responses towards innocuous substances, such as air-borne or food molecules | ||
Line 39: | Line 41: | ||
===Other mucosal surfaces=== | ===Other mucosal surfaces=== | ||
*Nasal deposition of some peptides can be used to induce tolerance, controlling both [[Humoral Factors of Innate Immune System|humoral]] and cellular responses | *Nasal deposition of some peptides can be used to induce tolerance, controlling both [[Humoral Factors of Innate Immune System|humoral]] and cellular responses | ||
− | *Administration of antigen in aerosol form to the lung has been used to control both | + | *Administration of antigen in aerosol form to the lung has been used to control both allergic and [[Autoimmune Diseases - Introduction#Autoimmune diseases|autoimmune]] responses |
==Regulatory T Cells== | ==Regulatory T Cells== | ||
Line 50: | Line 52: | ||
Regulatory T cells are unique in their use of a transcription repressor known as FoxP3 which is encoded by a gene on the X chromosome; rare deficiencies in FoxP3 are characterised by autoimmunity, primarily towards gut tissue, the thyroid, pancreative beta-cells and the skin. Sufferers are unable to produce regulatory T cells and the only known treatment is a bone marrow transplant from a MHC-identical sibling. | Regulatory T cells are unique in their use of a transcription repressor known as FoxP3 which is encoded by a gene on the X chromosome; rare deficiencies in FoxP3 are characterised by autoimmunity, primarily towards gut tissue, the thyroid, pancreative beta-cells and the skin. Sufferers are unable to produce regulatory T cells and the only known treatment is a bone marrow transplant from a MHC-identical sibling. | ||
− | + | ==Test yourself with the Immunology Flashcards== | |
− | + | [[Immune tolerance flashcards - Wikiblood|Immune tolerance flashcards]] | |
− | |||
− | |||
− | |||
− | |||
− | |||
[[Category:Immunology]] | [[Category:Immunology]] |
Revision as of 12:26, 16 November 2010
This article has been peer reviewed but is awaiting expert review. If you would like to help with this, please see more information about expert reviewing. |
Immune Tolerance
Immunological tolerance occurs when there is unresponsiveness towards particular antigens, so any further immune responses are prevented or suppressed. Tolerance is required to prevent:
- Potentially harmful inflammatory responses towards innocuous substances, such as air-borne or food molecules
- To prevent an immune attack against host tissue - this is known as self-tolerance
T Cell Tolerance
During T cell development within the thymus, genes encoding the T cell receptors are rearranged, resulting in adult cells that are able to recognise antigen fragments displayed by the host MHC molecule. Some receptors however will be self-reactive, i.e. they bind strongly to antigens expressed by the host's own tissues (autoantigens), inducing immune reactions that could be damaging to the host (autoimmune diseases); they must be deleted or suppressed.
Central Tolerance
Tolerance at a central level takes place within the thymus, and induces both positive and negative selections:
- During positive selection, cells passing through the thymic cortex encounter cortical epithelial cells expressing MHC molecules. Those with a suitable level of binding affinity for the MHC recieve 'survival' signals and apoptosis is prevented (at the same time cells lose either their CD4 or CD8 co-receptor)
- During negative selection, cells passing through the corticomedullary junction and thymic medulla once again encounter MHC molecules, on epithelial cells, dendritic cells and macrophages, this time bound to self-peptide. Cells bearing receptors that bind too strongly to this complex are deleted through induced apoptosis.
Peripheral Tolerance
It is inevitable that some self-reactive T cells will evade the thymic selection process and enter the peripheral circulation, because some self-antigens are not expressed in the thymus, and others will not show sufficient affinity to MHC to form the MHC: self-peptide complex required for negative selection in the thymus. Conversely some T cell receptors will not have enough affinity for their respective self-antigen to induce apoptosis. Peripheral tolerance describes unresponsiveness towards self-antigen which is developed outside the primary lymphoid organs. There are four ways this may be achieved in T cells:
- Ignorance
- Anergy
- Cell death
- Immune deviation/suppression
Ignorance can occur when self-reactive T cells cannot penetrate an endothelial barrier, when self-antigen is present in very low amounts, when self-antigen is present on cells that do not express or express low amounts of MHC or when self-antigen is presented without co-stimulation, which can lead to ignorance or anergy, depending on the type of antigen and the affinity to the TCR. Ignorance also occurs when the T cells are not present in sufficient numbers to mount an effective response.
Anergy is defined as a state where the T cell is still alive, but they fail to respond to stimulation from its specific T cell receptor and other receptors are required for activation. Anergy is easily induced in T cells in vivo by activation of T cell receptors without co-stimulation; it can be induced in vitro by the injection of potent superantigens (antigens that stimulate T cells with different receptor types, using the same T cell receptor V gene). Anergy occurs naturally when there is a downregulation of T cell receptors as a result of chronic stimulation. Anergy induced without co-stimulation can be reversed by IL-2.
Cell death; Peripheral deletion of T cells requires the engagement of Fas by Fas ligand. Deficiencies in Fas ligand lead to lymphoproliferative disorders. After activation by an antigen, T cells upregulate expression of Fas ligand - some tissues, such as the testis and retina, constitutively express Fas ligand to protect themselves from activated T cells
Cell death is also induced by TNF via the TNF receptor; CTLA-4 has recently also been implicated in cell death. The subsequent signalling cascade activates proteases, such as IL-1beta Converting Enzyme (ICE), that leads to cell apoptosis.
Immune deviation can be described as one immune response being selectively induced over another potential response - examples include Th2-derived cytokines, such as IL-10, which typically support antibody production, but can also down-regulate macrophage effector functions, such as antigen presentation, thereby suppressing the inflammatory response. Likewise, Th1-derived gamma-IFN can prevent Th0-Th2 differentiation. In the case of self-antigens, autoimmune diseases such as diabetes which are caused by Th1 cells can theoretically be prevented by 'antigen-primed' Th2 cells.
Mucosal tolerance
Mucosal tolerance is the systemic unresponsiveness towards antigens administered across mucosal surfaces. The highest antigenic load of the body surfaces occurs in the GI tract, so mucosal tolerance is also sometimes referred to as oral tolerance. When oral tolerance towards food antigens breaks down, inflammatory responses are induced. Gut associated lymphoid tissue is important in the development of oral tolerance: animals that lack Peyer’s patches and mesenteric lymph nodes do not develop oral tolerance. It is thought the liver and spleen may also play a role.
In the GI tract, high doses of antigen can cause anergy or cell death. Low doses can induce a T cell response where the antigen is taken up and presented, inducing a Th2-like cell response which produces cytokines that suppress the Th1 inflammatory response, such as IL-10 and TGF-beta. Although the cellular response is antigen-specific, the cytokines released are not. TGF-beta is known to inhibit the proliferation and function of B-cells, cytotoxic T cells and NK cells. This means tolerance induction to one antigen suppresses an immune response to a second associated antigen - this mechanism has been used to suppress some autoimmune diseases by feeding with an antigen isolated from the affected tissue. This is known as bystander suppression.
Other mucosal surfaces
- Nasal deposition of some peptides can be used to induce tolerance, controlling both humoral and cellular responses
- Administration of antigen in aerosol form to the lung has been used to control both allergic and autoimmune responses
Regulatory T Cells
A number of cell populations identified during studies on autoimmunity and organ transplantation have shown the capacity to suppress responses to self-antigen and therefore can be utilised to regulate rejection. Although once considered a tentative theory, this form of tolerance is now considered a major mechanism in the protection of host tissue from immune attack.
Known as regulatory T cells, CD4+ cells which are antigen-specific are currently thought to develop in the thymus. They usually release inhibitory cytokines, e.g. IL-4, IL-10 and TGF-beta and when their TCRs bind to an antigen, they do not proliferate themselves but suppress the proliferation of other naive T cells that would normally respond to that antigen. The mechanism of suppression is dependent on CTLA-4 on the regulatory T cell binding with B7 on the target T cell and then both cells binding the same antigen.
Regulatory T cells are unique in their use of a transcription repressor known as FoxP3 which is encoded by a gene on the X chromosome; rare deficiencies in FoxP3 are characterised by autoimmunity, primarily towards gut tissue, the thyroid, pancreative beta-cells and the skin. Sufferers are unable to produce regulatory T cells and the only known treatment is a bone marrow transplant from a MHC-identical sibling.